Skip to Content
Merck
All Photos(1)

Key Documents

Y0000427

Acarbose for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Acarbose, 4",6"-Dideoxy-4"-([1S]-[1,4,6/5]-4,5,6-trihydroxy-3-hydroxymethyl-2-yclohexenylamino)-maltotriose

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C25H43NO18
CAS Number:
Molecular Weight:
645.60
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

acarbose

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@@H]2CO)O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]4C=C(CO)[C@@H](O)[C@H](O)[C@H]4O

InChI

1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-/m1/s1

InChI key

XUFXOAAUWZOOIT-SXARVLRPSA-N

Gene Information

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Acarbose for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Modified tetrasaccharide that acts as a reversible α -glucosidase inhibitor.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

[Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Noriko Sakamoto et al.
Nihon rinsho. Japanese journal of clinical medicine, 63 Suppl 2, 451-456 (2005-03-23)
Christoph Rosak et al.
Current diabetes reviews, 5(3), 157-164 (2009-08-20)
The alpha-glucosidase inhibitor acarbose is administered to control blood glucose levels in type 2 diabetic patients and, in several countries, in those with impaired glucose tolerance. The efficacy and safety of the drug has been well established in these patient
R G Josse et al.
International journal of clinical practice, 60(7), 847-855 (2006-07-22)
The highly prevalent, prediabetic condition of impaired glucose tolerance (IGT) confers a high risk for type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). There is an emerging body of cost-effectiveness literature in the management of IGT. For acarbose, an
Markolf Hanefeld
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 12 Suppl 1, 56-59 (2006-04-22)
To discuss the influence of glucose excursions on intima-media thickness (IMT) and the potential benefits of treatment to reduce or reverse its effects on cardiovascular risk. The findings in pertinent reported studies are reviewed, and the efficacy of various interventions
Jean-Louis Chiasson
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 12 Suppl 1, 25-30 (2006-04-22)
To evaluate, in subjects with impaired glucose tolerance (IGT), the effect of acarbose on the incidence of diabetes, hypertension, and cardiovascular disease. The Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial was an international, multicenter, double-blind, placebo-controlled, randomized investigation, undertaken

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service